NO885032L - Paucilamellare lipidvesikler. - Google Patents

Paucilamellare lipidvesikler.

Info

Publication number
NO885032L
NO885032L NO885032A NO885032A NO885032L NO 885032 L NO885032 L NO 885032L NO 885032 A NO885032 A NO 885032A NO 885032 A NO885032 A NO 885032A NO 885032 L NO885032 L NO 885032L
Authority
NO
Norway
Prior art keywords
vessels
paucilamellar lipid
vesicles
paucilamellar
lipid
Prior art date
Application number
NO885032A
Other languages
English (en)
Norwegian (no)
Other versions
NO885032D0 (no
Inventor
Donald F H Wallach
Original Assignee
Micro Vesicular Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26699867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO885032(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Micro Vesicular Systems filed Critical Micro Vesicular Systems
Publication of NO885032D0 publication Critical patent/NO885032D0/no
Publication of NO885032L publication Critical patent/NO885032L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0017—Multi-phase liquid compositions
    • C11D17/0021—Aqueous microemulsions
    • C—CHEMISTRY; METALLURGY
    • C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
    • C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
    • C11D17/00—Detergent materials or soaps characterised by their shape or physical properties
    • C11D17/0008—Detergent materials or soaps characterised by their shape or physical properties aqueous liquid non soap compositions
    • C11D17/0026—Structured liquid compositions, e.g. liquid crystalline phases or network containing non-Newtonian phase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/10—Insect repellent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S525/00—Synthetic resins or natural rubbers -- part of the class 520 series
    • Y10S525/936—Encapsulated chemical agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Road Signs Or Road Markings (AREA)
  • Cosmetics (AREA)
  • Excavating Of Shafts Or Tunnels (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO885032A 1987-03-13 1988-11-11 Paucilamellare lipidvesikler. NO885032L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2552587A 1987-03-13 1987-03-13
US07/157,571 US4911928A (en) 1987-03-13 1988-03-03 Paucilamellar lipid vesicles
PCT/US1988/000723 WO1988006883A1 (en) 1987-03-13 1988-03-08 Paucilamellar lipid vesicles

Publications (2)

Publication Number Publication Date
NO885032D0 NO885032D0 (no) 1988-11-11
NO885032L true NO885032L (no) 1988-11-11

Family

ID=26699867

Family Applications (1)

Application Number Title Priority Date Filing Date
NO885032A NO885032L (no) 1987-03-13 1988-11-11 Paucilamellare lipidvesikler.

Country Status (14)

Country Link
US (1) US4911928A (de)
EP (1) EP0352282B1 (de)
JP (1) JP2589173B2 (de)
KR (1) KR960009647B1 (de)
AT (1) ATE71289T1 (de)
AU (1) AU605581B2 (de)
BR (1) BR8807410A (de)
CA (1) CA1289419C (de)
DE (1) DE3867637D1 (de)
DK (1) DK633388D0 (de)
HU (1) HUT53279A (de)
NO (1) NO885032L (de)
NZ (1) NZ223843A (de)
WO (1) WO1988006883A1 (de)

Families Citing this family (260)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5628936A (en) * 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5147723A (en) * 1987-07-28 1992-09-15 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5474848A (en) * 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US5219538A (en) * 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
JP2617346B2 (ja) * 1987-03-13 1997-06-04 マイクロ ベシキュラー システムズ，インコーポレイテッド 表面活性剤とステロイドから形成される脂質小胞
US5234767A (en) * 1987-03-13 1993-08-10 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5023086A (en) * 1987-03-13 1991-06-11 Micro-Pak, Inc. Encapsulated ionophore growth factors
US5811119A (en) * 1987-05-19 1998-09-22 Board Of Regents, The University Of Texas Formulation and use of carotenoids in treatment of cancer
EP0324455A3 (de) * 1988-01-15 1991-03-27 Hans O. Ribi Neue polymerische Immuno-Adjuvans
US4895452A (en) * 1988-03-03 1990-01-23 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5019392A (en) * 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US5013497A (en) * 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5032457A (en) * 1988-03-03 1991-07-16 Micro Vesicular Systems, Inc. Paucilamellar lipid vesicles using charge-localized, single chain, nonphospholipid surfactants
US5160669A (en) * 1988-03-03 1992-11-03 Micro Vesicular Systems, Inc. Method of making oil filled paucilamellar lipid vesicles
US5019174A (en) * 1988-03-03 1991-05-28 Micro Vesicular Systems, Inc. Removing oil from surfaces with liposomal cleaner
US5104736A (en) * 1988-03-03 1992-04-14 Micro-Pak, Inc. Reinforced paucilamellar lipid vesicles
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5510117A (en) * 1989-03-09 1996-04-23 Micro-Pak, Inc. Entrapment vehicle and method
GB8906234D0 (en) * 1989-03-17 1989-05-04 Albright & Wilson Agrochemical suspensions
AU6524990A (en) * 1989-09-21 1991-04-18 Micro Vesicular Systems, Inc. Hybrid paucilamellar lipid vesicles
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
FR2657607B1 (fr) * 1990-01-30 1992-04-30 Durand Muriel Procede de protection de la dihydroxyacetone, dihydroxyacetone protegee par ce procede et produit cosmetique contenant une telle dihydroxyacetone protegee.
US5213810A (en) * 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
US5165994A (en) * 1990-06-05 1992-11-24 University Of Delaware Spontaneous equilbrium surfactant vesicles
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
WO1992003123A1 (en) * 1990-08-28 1992-03-05 Liposome Technology, Inc. Liposome alternative bilayer formulations
EP0550463B1 (de) * 1990-09-06 1996-06-26 S.C. Johnson & Son, Inc. Verfahren zur stabilisierung von liposomen sowie diese enthaltende mittel
US5145604A (en) * 1990-09-19 1992-09-08 S. C. Johnson & Son, Inc. Aqueous emulsion and aerosol delivery system using same
US5091111A (en) * 1990-09-19 1992-02-25 S. C. Johnson & Son, Inc. Aqueous emulsion and aersol delivery system using same
US5256422A (en) * 1991-03-28 1993-10-26 Micro Vesicular Systems, Inc. Lipid vesicle containing water-in-oil emulsions
CA2108039C (en) * 1991-03-28 2003-06-10 Elizabeth C. Albert Lipid vesicle containing water-in-oil emulsions
DE4121945C2 (de) * 1991-07-03 1993-11-04 Merz & Co Gmbh & Co Verfahren zur herstellung von stabilen, hydrophilen oder ambiphilen creme-zubereitungen, enthaltend vesikulaere bestandteile, stabile creme-zubereitungen mit vesikulaeren bestandteilen und deren verwendung
US5213805A (en) * 1991-07-25 1993-05-25 Micro Vesicular Systems, Inc. Lipid vesicles having n,n-dimethylamide derivatives as their primary lipid
US5405615A (en) * 1991-09-17 1995-04-11 Micro Vesicular Systems, Inc. Sucrose distearate lipid vesicles
US5643600A (en) * 1991-09-17 1997-07-01 Micro-Pak, Inc. Lipid vesicles containing avocado oil unsaponifiables
US5260065A (en) * 1991-09-17 1993-11-09 Micro Vesicular Systems, Inc. Blended lipid vesicles
US5439967A (en) * 1991-09-17 1995-08-08 Micro Vesicular Systems, Inc. Propylene glycol stearate vesicles
EP0683673A4 (de) * 1992-12-02 1996-06-26 Micro Vesicular Systems Antacidum mit verlängerter wirkdauer.
US5393527A (en) * 1993-01-04 1995-02-28 Becton, Dickinson And Company Stabilized microspheres and methods of preparation
AU6018894A (en) * 1993-01-15 1994-08-15 Micro Vesicular Systems, Inc. Method of inhibiting viral reproduction
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
JPH09510433A (ja) 1993-12-17 1997-10-21 マイクロパック インコーポレイテッド 生物学的に活性な物質を細胞に送達する方法
BR9506885A (pt) * 1994-02-24 1997-08-19 Micro Pak Inc Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US5629021A (en) * 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
FR2730928B1 (fr) * 1995-02-23 1997-04-04 Oreal Composition a base de vesicules lipidiques a ph acide et son utilisation en application topique
US5599548A (en) * 1995-05-08 1997-02-04 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing fatty acid amides and retinol or retinyl ester
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
US5902604A (en) * 1995-06-06 1999-05-11 Board Of Regents, The University Of Texas System Submicron liposome suspensions obtained from preliposome lyophilizates
US5834014A (en) * 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US5874105A (en) * 1996-01-31 1999-02-23 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US6183774B1 (en) 1996-01-31 2001-02-06 Collaborative Laboratories, Inc. Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts
US6071535A (en) * 1996-01-31 2000-06-06 Collaborative Laboratories, Inc. Lipid vesicles formed with alkylammonium fatty acid salts
US5662957A (en) * 1996-05-03 1997-09-02 Novavax, Inc. Oil containing lipid vesicles with marine applications
US5700679A (en) * 1996-06-07 1997-12-23 Novavax, Inc. Lipid vesicles having a bilayer containing a surfactant with anti-viral and spermicidal activity
US5846551A (en) * 1996-06-10 1998-12-08 E-L Management Corp. Water-based makeup compositions and methods for their preparation
US5955092A (en) * 1996-09-27 1999-09-21 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an n-substituted fatty acid amide and retinol or retinyl ester
US5747051A (en) * 1996-09-27 1998-05-05 Elizabeth Arden Co., Division Of Conopco, Inc. Skin care compositions containing an amide of a hydroxy fatty acid and a retinoid
US5935572A (en) * 1997-01-10 1999-08-10 Collaborative Laboratories, Inc. Composition containing protease separate from glycosidase for removing nits in treating lice infestation
US6039960A (en) * 1997-05-28 2000-03-21 E-L Management Corp. Water containing wax-based product
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
TW476788B (en) 1998-04-08 2002-02-21 Kimberly Clark Co A cleanser and the making process thereof
GB9824024D0 (en) * 1998-11-03 1998-12-30 Unilever Plc Shampoo compositions
AU770803B2 (en) * 1998-12-23 2004-03-04 Idea Ag Improved formulation for topical non-invasive application in vivo
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
DK1031347T3 (da) 1999-01-27 2002-07-08 Idea Ag Transnasal transport/immunisering med meget tilpasselige bærere
US6080211A (en) * 1999-02-19 2000-06-27 Igen, Inc. Lipid vesicle-based fuel additives and liquid energy sources containing same
CA2309373A1 (en) * 1999-05-27 2000-11-27 Johnson & Johnson Consumer Companies, Inc. Novel topical formulations
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US6309664B1 (en) 1999-09-15 2001-10-30 Igen, Incorporated Methods, uses and compositions of fluid petrolatum
US6534078B1 (en) * 1999-10-18 2003-03-18 Natural Pest Fx, Inc. Micro-encapsulated pepper-mustard composition and methods of using the same
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
US6540991B2 (en) 2001-04-06 2003-04-01 3M Innovative Properties Company Stabilized active materials
US6562361B2 (en) 2001-05-02 2003-05-13 3M Innovative Properties Company Pheromone immobilized in stable hydrogel microbeads
AU2002353774A1 (en) * 2001-08-01 2003-03-24 The Procter And Gamble Company Products and methods for treating microbial infections
EP1423430A1 (de) * 2001-08-16 2004-06-02 Lyfjathroun H.F., Biopharmaceuticals Verfahren zur ex-vivo-herstellung von antikörpern
US6709663B2 (en) * 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
DE60137229D1 (de) * 2001-10-22 2009-02-12 Viroblock Sa Non-phospholipid Vesikel (npLV) und ihre Verwendung in kosmetischen, therapeutischen und prophylaktischen Anwendungen
US20030129213A1 (en) * 2001-12-26 2003-07-10 Gonzalez Anthony D. Meta-stable insect repellent emulsion composition and method of use
US20030219465A1 (en) * 2002-05-23 2003-11-27 Suresh Kumar Gidwani Composition for delivery of dithranol
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US20040087564A1 (en) * 2002-10-31 2004-05-06 Wright D. Craig Delivery composition and method
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
CN1918175A (zh) 2003-09-29 2007-02-21 托皮根药品公司 治疗包括炎症状况的疾病的寡核苷酸组合物和方法
CA2708440C (en) 2004-04-05 2013-05-14 Kanagawa University Emulsification dispersants, a method for emulsification and dispersion using the emulsification dispersants, emulsions, and emulsion fuels
US8034796B2 (en) * 2004-04-07 2011-10-11 The University Of Georgia Research Foundation, Inc. Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
EA200601648A1 (ru) 2004-04-07 2007-04-27 Зе Юниверсити Оф Джорджия Рисерч Фаундейшн, Инк. Глюкозамин и общие пролекарства глюкозамин/противовоспалительный агент, композиции и способы
JP4616602B2 (ja) * 2004-09-16 2011-01-19 大日本塗料株式会社 単分散粒子の製造方法
US8119790B2 (en) 2004-10-29 2012-02-21 Topigen Pharmaceuticals Inc. Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
JP4533420B2 (ja) * 2004-12-22 2010-09-01 日東電工株式会社 線維化抑制のための薬物担体および薬物担体キット
HUE056941T2 (hu) * 2004-12-22 2022-04-28 Nitto Denko Corp Gyógyszerhordozó és gyógyszerhordozó kit fibrózis gátlására
US20080045575A1 (en) * 2004-12-29 2008-02-21 Van Dyke Thomas E Delivery of H2 Antagonists
CN101111306B (zh) 2005-01-28 2010-09-29 独立行政法人科学技术振兴机构 经脱水缩合反应可发生相转移的分子集合体及其相转移方法
EP1910297B1 (de) 2005-07-11 2016-05-25 Aerie Pharmaceuticals, Inc. Isochinolinverbindungen
US20070077292A1 (en) 2005-10-03 2007-04-05 Pinsky Mark A Compositions and methods for improved skin care
HUE026136T2 (en) 2005-10-18 2016-05-30 Novavax Inc Functional influenza virus-like particles (VLP-K)
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
AU2007252192B2 (en) * 2006-05-19 2013-10-17 Topigen Pharmaceuticals Inc. Oligonucleotides affecting expression of phosphodiesterases
BRPI0712074A2 (pt) * 2006-05-19 2012-01-17 Viroblock S A composição para desativar um vìrus envelopado
WO2008036540A2 (en) 2006-09-20 2008-03-27 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2008083275A2 (en) * 2006-12-28 2008-07-10 3M Innovative Properties Company Dental filler and methods
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US20100098752A1 (en) * 2007-01-18 2010-04-22 Pinsky Mark A Materials and Methods for Delivering Antioxidants into the Skin
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
CA2692171C (en) 2007-06-22 2019-10-22 Randolph Watnick Methods and uses thereof of prosaposin
FR2917976B1 (fr) * 2007-06-29 2010-05-28 Galderma Sa Composition dermatologique comprenant des vehicules lipidiques de calcitriol, son procede de preparation et son utilisation
EP2175883A4 (de) 2007-07-19 2011-11-30 Novavax Inc Chimäre varicella zoster virus-virusähnliche partikel
ES2710498T3 (es) * 2007-12-26 2019-04-25 Mark A Pinsky Formulaciones de colágeno para la mejora del cuidado de la piel
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US10251839B2 (en) * 2008-01-22 2019-04-09 Igi Laboratories, Inc. Lipid vesicles derived from olive oil fatty acids
CA2724179A1 (en) 2008-05-15 2009-11-19 Topigen Pharmaceuticals Inc. Oligonucleotides for treating inflammation and neoplastic cell proliferation
RU2553225C2 (ru) * 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US20110229544A1 (en) * 2008-11-26 2011-09-22 Viroblock S.A. Methods for Inhibiting Gram-Postive Bacteria Using Non-Phospholipid Lipid Vesicules
SG172022A1 (en) 2008-12-09 2011-07-28 Novavax Inc Modified rsv f proteins and methods of their use
JP2012525386A (ja) 2009-05-01 2012-10-22 アエリエ・ファーマシューティカルズ・インコーポレーテッド 疾患の治療のための二重機構阻害剤
EP2459187B1 (de) 2009-07-29 2021-01-06 Olsen, Elise Zusammensetzungen und verfahren zur hemmung von haarwachstum
WO2011038073A1 (en) * 2009-09-23 2011-03-31 Formatech, Inc. Methods for the preparation of liposomes comprising docetaxel
US10143652B2 (en) 2009-09-23 2018-12-04 Curirx Inc. Methods for the preparation of liposomes
EP3366695B1 (de) 2009-12-17 2021-07-07 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
EP3511017A1 (de) 2010-09-27 2019-07-17 Siwa Corporation Selektive entfernung von altersmodifizierten zellen zur behandlung von atherosklerose
CA2817005C (en) 2010-11-05 2018-09-11 Novavax Inc. Rabies glycoprotein virus-like particles (vlps)
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
EP2646107A2 (de) 2010-12-01 2013-10-09 Spinal Modulation Inc. Wirkstofffreisetzungssysteme für selektive nervenmodulation
JP6081995B2 (ja) 2011-06-17 2017-02-15 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 癌の処置における治療抗体の標的としてのＦｒｉｚｚｌｅｄ２
WO2013003803A1 (en) 2011-06-29 2013-01-03 Avidas Pharmaceuticals Llc Topical formulations including lipid microcapsule delivery vehicles and their uses
EP2734621B1 (de) 2011-07-22 2019-09-04 President and Fellows of Harvard College Beurteilung und verbesserung einer nukleasespaltungsspezifität
EP3560509B1 (de) 2011-12-22 2024-01-31 Children's Medical Center Corporation Aus saposin-a gewonnene peptide und verwendungen davon
WO2013119602A1 (en) 2012-02-06 2013-08-15 President And Fellows Of Harvard College Arrdc1-mediated microvesicles (armms) and uses thereof
AU2013202595B2 (en) 2012-03-30 2016-04-21 Biogen Ma Inc. Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome
CN111254145A (zh) 2013-03-14 2020-06-09 Ionis制药公司 用于调节tau表达的组合物和方法
US10376562B2 (en) 2013-03-15 2019-08-13 The Jackson Laboratory Methods for promoting wound healing and hair growth comprising GDNF administration
US20140275160A1 (en) 2013-03-15 2014-09-18 Aerie Pharmaceuticals, Inc. Combination therapy
US20140325490A1 (en) * 2013-04-25 2014-10-30 Hewlett-Packard Development Company, L.P. Classifying Source Code Using an Expertise Model
TWI772856B (zh) 2013-07-19 2022-08-01 美商百健Ｍａ公司 用於調節τ蛋白表現之組合物
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
MX2016003419A (es) 2013-09-19 2016-10-10 Novavax Inc Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
RU2016122918A (ru) * 2013-12-23 2018-01-30 Дэрмопартнерс, С.Л. Способ получения липосом ретинальдегида или других предшественников ретиноевой кислоты и образующийся таким образом продукт
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
CA2961603C (en) 2014-09-19 2021-07-13 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9816080B2 (en) 2014-10-31 2017-11-14 President And Fellows Of Harvard College Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
WO2016138287A1 (en) 2015-02-25 2016-09-01 Washington University METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs
JP6866345B2 (ja) 2015-07-23 2021-04-28 ベーリンガー・インゲルハイム・インターナショナル・ゲーエムベーハー Ｉｌ−２３ａ及びｂ細胞活性化因子（ｂａｆｆ）を標的とする化合物及びその使用
RU2730625C2 (ru) 2015-09-03 2020-08-24 Новавакс, Инк. Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
BR112018007422A2 (pt) 2015-10-13 2018-10-30 Siwa Corp anticorpos anti-age e métodos de uso dos mesmos
US10167457B2 (en) 2015-10-23 2019-01-01 President And Fellows Of Harvard College Nucleobase editors and uses thereof
KR102579582B1 (ko) 2015-11-17 2023-09-15 에어리 파마슈티컬즈, 인코포레이티드 키나아제 억제제 및 이의 중간체의 제조 방법
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US10435682B2 (en) 2016-02-19 2019-10-08 University Of South Florida Arginine deiminase gene therapy for disordered proteins
EP3337829B1 (de) 2016-02-19 2020-01-08 Siwa Corporation Verfahren und zusammensetzung zur behandlung von krebs, abtötung von metastasierenden krebszellen und verhinderung von krebsmetastasen mit einem antikörper gegen fortgeschrittene glykierungsendprodukte
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP7152392B2 (ja) 2016-06-08 2022-10-12 ザ チルドレンズ メディカル センター コーポレーション 操作されたボツリヌスニューロトキシン
EP3475306A1 (de) 2016-06-23 2019-05-01 Siwa Corporation Impfstoffe zur verwendung bei der behandlung verschiedener erkrankungen und störungen
AU2017292922B9 (en) 2016-07-08 2022-05-12 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
SG11201900907YA (en) 2016-08-03 2019-02-27 Harvard College Adenosine nucleobase editors and uses thereof
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
CN106268551B (zh) * 2016-08-09 2018-11-20 中国石油大学(华东) 一种具有光捕获功能的多级复合微胶囊的制备方法
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
CA3035566A1 (en) 2016-08-31 2018-03-08 Aerie Pharmaceuticals, Inc. Ophthalmic compositions
JOP20190065A1 (ar) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc مركبات وطرق لتقليل التعبير عن tau
WO2018067546A1 (en) 2016-10-03 2018-04-12 President And Fellows Of Harvard College Delivery of therapeutic rnas via arrdc1-mediated microvesicles
SG11201903089RA (en) 2016-10-14 2019-05-30 Harvard College Aav delivery of nucleobase editors
CA3048479A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Gene editing of pcsk9
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510038A (ja) 2017-03-09 2020-04-02 プレジデント アンド フェローズ オブ ハーバード カレッジ がんワクチン
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
US11268082B2 (en) 2017-03-23 2022-03-08 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable DNA binding proteins
KR20190135027A (ko) 2017-03-31 2019-12-05 에어리 파마슈티컬즈, 인코포레이티드 아릴 시클로프로필-아미노-이소퀴놀리닐 아미드 화합물
EP3609923A1 (de) 2017-04-13 2020-02-19 Siwa Corporation Humanisierter monoklonaler advanced-glycation-endproduct-antikörper
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
CN111148509A (zh) 2017-07-24 2020-05-12 诺瓦瓦克斯股份有限公司 治疗呼吸系统疾病的方法和组合物
EP3658573A1 (de) 2017-07-28 2020-06-03 President and Fellows of Harvard College Verfahren und zusammensetzungen zur entwicklung von basiseditoren unter verwendung von phagenunterstützter kontinuierlicher entwicklung (pace)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
JP2021500871A (ja) 2017-09-29 2021-01-14 ザ チルドレンズ メディカル センター コーポレーション ニューロトキシン様トキシンおよびそれらの使用
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
US11541120B2 (en) 2017-12-05 2023-01-03 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
US11254704B2 (en) 2018-01-05 2022-02-22 University Of South Florida Compounds and methods for reducing or inhibiting aggregation of proteins in a subject
US20220307001A1 (en) 2018-02-27 2022-09-29 President And Fellows Of Harvard College Evolved cas9 variants and uses thereof
US10507226B1 (en) 2018-05-02 2019-12-17 University Of South Florida N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease
KR20210023832A (ko) 2018-05-11 2021-03-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 단일염기다형성을 편집하는 방법
EP3797160A1 (de) 2018-05-23 2021-03-31 The Broad Institute Inc. Baseneditoren und verwendungen davon
WO2020023532A1 (en) 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
US20240173430A1 (en) 2018-09-05 2024-05-30 The Broad Institute, Inc. Base editing for treating hutchinson-gilford progeria syndrome
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
US20220282275A1 (en) 2018-11-15 2022-09-08 The Broad Institute, Inc. G-to-t base editors and uses thereof
WO2020181202A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to t:a base editing through adenine deamination and oxidation
WO2020181180A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. A:t to c:g base editors and uses thereof
WO2020181195A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through adenine excision
US20220170013A1 (en) 2019-03-06 2022-06-02 The Broad Institute, Inc. T:a to a:t base editing through adenosine methylation
WO2020181178A1 (en) 2019-03-06 2020-09-10 The Broad Institute, Inc. T:a to a:t base editing through thymine alkylation
BR112021018607A2 (pt) 2019-03-19 2021-11-23 Massachusetts Inst Technology Métodos e composições para editar sequências de nucleotídeos
WO2020210751A1 (en) 2019-04-12 2020-10-15 The Broad Institute, Inc. System for genome editing
US20220307003A1 (en) 2019-04-17 2022-09-29 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3973054A1 (de) 2019-05-20 2022-03-30 The Broad Institute Inc. Aav-abgabe von nukleobasen-editoren
EP4010474A1 (de) 2019-08-08 2022-06-15 The Broad Institute, Inc. Basiseditoren mit diversifiziertem zielbereich
WO2021030666A1 (en) 2019-08-15 2021-02-18 The Broad Institute, Inc. Base editing by transglycosylation
CA3153563A1 (en) 2019-09-09 2021-03-18 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
WO2021072328A1 (en) 2019-10-10 2021-04-15 The Broad Institute, Inc. Methods and compositions for prime editing rna
US20230086199A1 (en) 2019-11-26 2023-03-23 The Broad Institute, Inc. Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
CN114981426A (zh) 2019-12-03 2022-08-30 比姆医疗股份有限公司 合成向导rna、其组合物、方法和用途
CA3166153A1 (en) 2020-01-28 2021-08-05 The Broad Institute, Inc. Base editors, compositions, and methods for modifying the mitochondrial genome
US20230108687A1 (en) 2020-02-05 2023-04-06 The Broad Institute, Inc. Gene editing methods for treating spinal muscular atrophy
US20230235309A1 (en) 2020-02-05 2023-07-27 The Broad Institute, Inc. Adenine base editors and uses thereof
US20230159913A1 (en) 2020-04-28 2023-05-25 The Broad Institute, Inc. Targeted base editing of the ush2a gene
AU2021264007A1 (en) 2020-05-01 2022-12-08 Siwa Corporation Methods of treating infections
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
EP4237556A2 (de) 2020-10-28 2023-09-06 Children's Medical Center Corporation Verkürztes modifiziertes rekombinantes adamts13 und verwendungen davon
WO2022125776A2 (en) 2020-12-09 2022-06-16 Siwa Corporation Methods and compositions for treating kidney diseases
JP2024507533A (ja) 2021-02-19 2024-02-20 ビーム・セラピューティクス・インコーポレイテッド 遺伝子治療のための組み換え狂犬病ウイルス
EP4314265A2 (de) 2021-03-23 2024-02-07 Beam Therapeutics Inc. Neuartige crispr-enzyme, verfahren, systeme und verwendungen davon
AU2022256513A1 (en) 2021-04-16 2023-11-02 Beam Therapeutics Inc. Genetic modification of hepatocytes
WO2022256578A2 (en) 2021-06-02 2022-12-08 Beam Therapeutics Inc. Circular guide rnas for crispr/cas editing systems
US20240287487A1 (en) 2021-06-11 2024-08-29 The Broad Institute, Inc. Improved cytosine to guanine base editors
EP4373931A1 (de) 2021-07-23 2024-05-29 Beam Therapeutics Inc. Guide-rnas für crispr/cas-editiersysteme
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
CN118369429A (zh) 2021-09-08 2024-07-19 比姆医疗股份有限公司 病毒引导rna递送
WO2023076898A1 (en) 2021-10-25 2023-05-04 The Broad Institute, Inc. Methods and compositions for editing a genome with prime editing and a recombinase
KR20240110844A (ko) 2021-11-23 2024-07-16 셀렉티스 에스.에이. 개선된 온-타겟/오프-타겟 활성 비율을 갖는 신규 tale 단백질 스캐폴드
WO2023102538A1 (en) 2021-12-03 2023-06-08 The Broad Institute, Inc. Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
EP4441073A2 (de) 2021-12-03 2024-10-09 The Broad Institute, Inc. Selbstanordnende virusähnliche partikel zur abgabe von nukleinsäureprogrammierbaren fusionsproteinen und verfahren zur herstellung und verwendung davon
AU2022413670A1 (en) 2021-12-17 2024-07-04 Beam Therapeutics Inc. Crispr enzymes, methzods, systems and uses thereof
AU2023248451A1 (en) 2022-04-04 2024-10-17 President And Fellows Of Harvard College Cas9 variants having non-canonical pam specificities and uses thereof
WO2023196772A1 (en) 2022-04-04 2023-10-12 Beam Therapeutics Inc. Novel rna base editing compositions, systems, methods and uses thereof
WO2023205687A1 (en) 2022-04-20 2023-10-26 The Broad Institute, Inc. Improved prime editing methods and compositions
WO2023212715A1 (en) 2022-04-28 2023-11-02 The Broad Institute, Inc. Aav vectors encoding base editors and uses thereof
WO2023230613A1 (en) 2022-05-27 2023-11-30 The Broad Institute, Inc. Improved mitochondrial base editors and methods for editing mitochondrial dna
WO2023240137A1 (en) 2022-06-08 2023-12-14 The Board Institute, Inc. Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
WO2024040083A1 (en) 2022-08-16 2024-02-22 The Broad Institute, Inc. Evolved cytosine deaminases and methods of editing dna using same
WO2024059791A1 (en) 2022-09-16 2024-03-21 Beam Therapeutics Inc. Large serine recombinases, systems and uses thereof
WO2024077267A1 (en) 2022-10-07 2024-04-11 The Broad Institute, Inc. Prime editing methods and compositions for treating triplet repeat disorders
WO2024102157A1 (en) 2022-11-09 2024-05-16 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2024138087A2 (en) 2022-12-23 2024-06-27 The Broad Institute, Inc. Methods and compositions for modulating cellular factors to increase prime editing efficiencies
WO2024155745A1 (en) 2023-01-18 2024-07-25 The Broad Institute, Inc. Base editing-mediated readthrough of premature termination codons (bert)
WO2024155741A1 (en) 2023-01-18 2024-07-25 The Broad Institute, Inc. Prime editing-mediated readthrough of premature termination codons (pert)
WO2024168147A2 (en) 2023-02-09 2024-08-15 The Broad Institute, Inc. Evolved recombinases for editing a genome in combination with prime editing
WO2024206125A1 (en) 2023-03-24 2024-10-03 The Broad Institute, Inc. Use of prime editing for treating sickle cell disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
FR2315991A1 (fr) * 1975-06-30 1977-01-28 Oreal Procede de fabrication de dispersions aqueuses de spherules lipidiques et nouvelles compositions correspondantes
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
GB1578776A (en) * 1976-06-10 1980-11-12 Univ Illinois Hemoglobin liposome and method of making the same
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
FR2416008A1 (fr) * 1978-02-02 1979-08-31 Oreal Lyophilisats de liposomes
US4377567A (en) * 1978-10-02 1983-03-22 The Procter & Gamble Company Lipid membrane drug delivery
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
FR2465780A1 (fr) * 1979-09-18 1981-03-27 Oreal Nouveaux tensio-actifs non ioniques, leur procede de preparation et composition les contenant
DE3070993D1 (en) * 1979-12-20 1985-09-19 Dennis Chapman Polymerisable phospholipids and polymers thereof, methods for their preparation, methods for their use in coating substrates and forming liposomes and the resulting coated substrates and liposome compositions
EP0032578B1 (de) * 1980-01-16 1984-07-25 Hans Georg Prof. Dr. Weder Verfahren und Dialysiereinrichtung zur Herstellung von Bilayer-Vesikeln und Verwendung der Bilayer-Vesikel
FR2485921A1 (fr) * 1980-07-01 1982-01-08 Oreal Composition cosmetique a base d'une dispersion aqueuse de spherules lipidiques
EP0043327B1 (de) * 1980-07-01 1984-01-18 L'oreal Verfahren zur Herstellung stabiler Dispersionen in einer wässrigen Phase von mindestens einer flüssigen, nicht mit Wasser mischbaren Phase und die entsprechenden Dispersionen
US4564599A (en) * 1982-08-23 1986-01-14 The Liposome Company, Inc. Liposome composition for lupus assay
JPS5916534A (ja) * 1982-07-19 1984-01-27 Lion Corp 非イオン性界面活性剤系ベシクル分散液
US4551288A (en) * 1982-08-16 1985-11-05 Sandoz, Inc. Processes for the preparation of liposome drug delivery systems
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
JPS59106423A (ja) * 1982-12-08 1984-06-20 Hiroshi Kiwada リポソ−ム
FR2543018B1 (fr) * 1983-03-22 1985-07-26 Oreal Procede de preparation de vesicules lipidiques par vaporisation de solvants
JPS6072831A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
JPS6072830A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
FR2553002B1 (fr) * 1983-10-06 1992-03-27 Centre Nat Rech Scient Procede perfectionne d'obtention de liposomes unilamellaires de diametres eleves, leur application pharmacologique pour l'encapsulage d'un principe actif en vue de son administration extemporanee et dispositif correspondant
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
US4695554A (en) * 1984-02-14 1987-09-22 Becton Dickinson And Company Sac or liposome containing dye (sulforhodamine) for immunoassay
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4619913A (en) * 1984-05-29 1986-10-28 Matrix Pharmaceuticals, Inc. Treatments employing drug-containing matrices for introduction into cellular lesion areas
FR2571963B1 (fr) * 1984-10-24 1987-07-10 Oreal Composition a usage cosmetique ou pharmaceutique contenant des niosomes et au moins un polyamide hydrosoluble et procede de preparation de cette composition.
JPS61207324A (ja) * 1985-03-11 1986-09-13 Agency Of Ind Science & Technol リポソ−ム

Also Published As

Publication number Publication date
NO885032D0 (no) 1988-11-11
KR960009647B1 (en) 1996-07-23
DE3867637D1 (de) 1992-02-20
JP2589173B2 (ja) 1997-03-12
CA1289419C (en) 1991-09-24
NZ223843A (en) 1990-04-26
BR8807410A (pt) 1990-04-10
HUT53279A (en) 1990-10-28
JPH02502094A (ja) 1990-07-12
AU1541688A (en) 1988-10-10
US4911928A (en) 1990-03-27
WO1988006883A1 (en) 1988-09-22
EP0352282A1 (de) 1990-01-31
DK633388A (da) 1988-11-11
ATE71289T1 (de) 1992-01-15
AU605581B2 (en) 1991-01-17
DK633388D0 (da) 1988-11-11
KR890700339A (ko) 1989-04-24
EP0352282B1 (de) 1992-01-08

Similar Documents

Publication Publication Date Title
NO885032L (no) Paucilamellare lipidvesikler.
NO885605L (no) Fremgangsmaate for fremstilling av smoereolje.
ES2131051T3 (es) Liposomas como agentes de contraste para la formacion de imagenes ultrasonicas.
DE3867415D1 (de) Verfahren zur herstellung laminierter werkstoffe.
FI881743A0 (fi) Menetelmä bifunktionaalisten proteiinien valmistamiseksi
ES535914A0 (es) Procedimiento para producir una preparacion de gel o preparacion que contiene gel
NO884310L (no) Fremgangsmaate for fremstilling av noeytralt papir.
DE3586095D1 (de) Herstellung von lipid-vesikeln.
ES530045A0 (es) Procedimiento para la obtencion de acidos quinoloncarboxilicos
ES2014481B3 (es) Procedimiento para la fabricacion de vidrieras laminadas.
DK554289A (da) Helium-neonlaser
IT1191525B (it) Procedimento per la fabbricazione di vasche per macchine
IT1176953B (it) Procedimento per la produzione di poliesteri aromatici
IT1227316B (it) Carda per la produzione di veli di fibre e simili
MX11506A (es) Procedimiento para la preparacion de colorantes diazoicos hidrosolubles
DE3850601D1 (de) Verfahren zur Herstellung von Phospholipidderivate.
IT8867697A0 (it) Procedimento per provocare la rottura di una emulsione
ES531129A0 (es) Procedimiento para aislar agentes tensioactivos lipidicos
NO885446D0 (no) Fremgangsmaate for fremstilling av kinolincarboxylsyrer.
ES1005242Y (es) Microscopio simplificado
IT8723266A0 (it) Procedimento per la fabbricazione di tappeti e simili.
ES530905A0 (es) Procedimiento para preparar los antipodas opticos de 8-amino-2-metil-4-fenil-1, 2, 3, 4-tetrahidroisoquinoleina
DE68912914D1 (de) Herstellung von Thiophosphatsalzen.
IT8348464A0 (it) Carta candeggiata otticamente procedimento per la preparazione di
DE69008733D1 (de) Interesterifikation von phospholipiden.